หน้าแรก
ค้นหา
Dr. Joel Neal on Impact of PD-L1 Tests on Pembrolizumab, Nivolumab Efficacy in Frontline NSCLC
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Joel Neal on Impact of PD-L1 Tests on Pembrolizumab, Nivolumab Efficacy in Frontline NSCLC
PD-L1 testing in first-line treatment of NSCLC
Dr. Ferris on Impact of FDA Approval of Pembrolizumab in Patients With Head and Neck Cancer
How does the safety and efficacy differ between the anti-PD-1 antibodies pembrolizumab & nivolumab?
Dr. Neal on Immunotherapy Combinations in Lung Cancer
First-Line Therapy in PD-L1–Advanced NSCLC
Phase III trial: Pembrolizumab for patients w/ metastatic NSCLC that expresses PD-1
Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance
Dr. Hirsch on Value of PD-L1 Testing in Patients With Lung Cancer
Dr. Neal on Ongoing Trials of Immunotherapy for Lung Cancer
Dr. Levy on Impact of Nivolumab, Pembrolizumab Approvals in NSCLC
PD-L1 Testing for NSCLC
PD-L1 Testing in Advanced Lung Cancer
Cancer Genetics offers the FDA-approved PD-L1 Testing
Results of KEYNOTE-024 trial of pembrolizumab in NSCLC
Molecular Testing for Early Stage Lung Cancer Patients - Is it Necessary?
Reliability of PD-L1 Testing in NSCLC
KEYNOTE-024 update: pembrolizumab vs platinum-based chemotherapy in NSCLC
Dr. Neal on Exciting Advancements in the Field of Lung Cancer
Molecular Testing in Melanoma: BRAF and PD-L1
